 |
|
RESEARCH
|
Research in the Wittrup group is predominantly
focused on the application of protein engineering
to the development of cancer therapeutics.
|
Tumor targeting
(NCI CA101830, NCI CCNE) |
Development of
optimized proteins and protocols for selectively
delivering radiometals and toxins to tumor cells.
Lab Researchers: Michael
Schmidt, Greg
Thurber, Margaret E. Pawlowski, Kelly Davis, Chris Pirie
Collaborators: John Frangioni, BIDMC,
Sangeeta Bhatia, MIT, Jack Wands, Brown University, Michael Rosenblum, MD Anderson Cancer Center, Steve
Larson, MSKCC. |
| Engineered
Antibody EGFR Antagonist Cancer Therapeutics (NCI
CA96504) |
Structure/function & trafficking
studies of antibody antagonism of the epidermal
growth factor receptor, involved in many
cancers.
Lab Researchers: Jamie Spangler, Steve
Sazinsky, Ben Hackel
Collaborators: Doug
Lauffenburger, MIT, Bruce
Tidor, MIT, and John
Kuriyan, UC Berkeley. |
Tumor Immunotherapy
(NIAID AI065824) |
Presentation of tumor antigens
to the immune system together with stimulatory
signals that mimic a pathogenic infection to
attempt to raise a protective immune response.
Engineering altered binding properties of
interleukin 2 to enhance T cell
signaling properties.
Lab Researchers: Shanshan
Wu Howland, Eileen
Higham, Jordi Mata-Fink, Annie Gai, David Liu
Collaborators: David Hafler, Harvard, Jianzhu
Chen, MIT, Doug
Lauffenburger, MIT, Forest
White, MIT, and Garry
Nolan, Stanford. |
top |
|
|
|
